APLS Logo

Apellis Pharmaceuticals, Inc. (APLS) 

NASDAQ$25.11
Market Cap
$3.15B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
456 of 924
Rank in Industry
266 of 527

APLS Insider Trading Activity

APLS Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$000
Sells
$14,853,82153100

Related Transactions

Eisele JeffreyChief Development Officer0$04$57,149$-57,149
Chopas James GeorgeVP/Chief Accounting Officer0$05$105,912$-105,912
Lewis KarenChief People Officer0$04$147,094$-147,094
Baumal CarolineChief Medical Officer0$02$150,727$-150,727
Townsend Adam J.Chief Commercial Officer0$04$264,626$-264,626
Nicholson NurChief Technical Officer0$04$284,281$-284,281
Sullivan Timothy EugeneChief Financial Officer0$05$458,825$-458,825
Watson David O.General Counsel0$06$641,031$-641,031
DeLong Mark JeffreyChief Business & Strat Officer0$06$710,552$-710,552
Francois CedricChief Executive Officer0$04$854,932$-854,932
Dunlop A. Sinclairdirector0$03$3.86M$-3.86M
Deschatelets PascalChief Scientific Officer0$06$7.32M$-7.32M

About Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment â€¦

Insider Activity of Apellis Pharmaceuticals, Inc.

Over the last 12 months, insiders at Apellis Pharmaceuticals, Inc. have bought $0 and sold $14.85M worth of Apellis Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at Apellis Pharmaceuticals, Inc. have bought $10.16M and sold $32.96M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 500,000 shares for transaction amount of $20M was made by Morningside Venture Investments Ltd (10 percent owner) on 2021‑11‑18.

List of Insider Buy and Sell Transactions, Apellis Pharmaceuticals, Inc.

2025-03-05SaleWatson David O.General Counsel
5,569
0.0043%
$25.10$139,789-3.38%
2025-02-11SaleDeLong Mark JeffreyChief Business & Strat Officer
363
0.0003%
$28.54$10,360-9.11%
2025-01-29SaleDeschatelets PascalChief Scientific Officer
826
0.0007%
$29.52$24,386-6.91%
2025-01-29SaleFrancois CedricChief Executive Officer
2,824
0.0023%
$29.52$83,375-6.91%
2025-01-29SaleWatson David O.General Counsel
695
0.0006%
$29.52$20,519-6.91%
2025-01-29SaleSullivan Timothy EugeneChief Financial Officer
546
0.0004%
$29.52$16,120-6.91%
2025-01-29SaleDeLong Mark JeffreyChief Business & Strat Officer
365
0.0003%
$29.52$10,776-6.91%
2025-01-29SaleTownsend Adam J.Chief Commercial Officer
695
0.0006%
$29.52$20,519-6.91%
2025-01-29SaleNicholson NurChief Technical Officer
825
0.0007%
$29.52$24,357-6.91%
2025-01-29SaleLewis KarenChief People Officer
364
0.0003%
$29.52$10,747-6.91%
2025-01-29SaleEisele JeffreyChief Development Officer
278
0.0002%
$29.52$8,208-6.91%
2025-01-22SaleDeschatelets PascalChief Scientific Officer
3,948
0.0032%
$30.43$120,120-7.96%
2025-01-22SaleFrancois CedricChief Executive Officer
13,551
0.0109%
$30.43$412,296-7.96%
2025-01-22SaleWatson David O.General Counsel
3,323
0.0027%
$30.43$101,104-7.96%
2025-01-22SaleSullivan Timothy EugeneChief Financial Officer
3,088
0.0025%
$30.43$93,954-7.96%
2025-01-22SaleTownsend Adam J.Chief Commercial Officer
3,323
0.0027%
$30.43$101,104-7.96%
2025-01-22SaleDeLong Mark JeffreyChief Business & Strat Officer
1,396
0.0011%
$30.43$42,474-7.96%
2025-01-22SaleNicholson NurChief Technical Officer
3,948
0.0032%
$30.43$120,120-7.96%
2025-01-22SaleLewis KarenChief People Officer
1,751
0.0014%
$30.43$53,275-7.96%
2025-01-22SaleEisele JeffreyChief Development Officer
1,291
0.001%
$30.43$39,279-7.96%
Total: 359
*Gray background shows transactions not older than one year

Insider Historical Profitability

10.88%
Sullivan Timothy EugeneChief Financial Officer
128665
0.1025%
$3.23M114+1.94%
Morningside Venture Investments Ltd10 percent owner
12806342
10.203%
$321.57M90+6.91%
venBio Global Strategic Fund II L.P.10 percent owner
3579305
2.8517%
$89.88M10+31.35%
Hillhouse Capital Management, Ltd.10 percent owner
3527152
2.8101%
$88.57M10+31.35%
Cormorant Asset Management, LLC10 percent owner
3473925
2.7677%
$87.23M10+31.35%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$193,151,375
134
8.18%
$2.8B
$11,588,217
69
42.07%
$2.65B
$140,165,669
33
85.24%
$3.4B
$1,275,975,557
32
19.44%
$2.87B
$5,066,938
27
26.38%
$2.72B

APLS Institutional Investors: Active Positions

Increased Positions161+51.94%32M+26.74%
Decreased Positions139-44.84%22M-18.66%
New Positions60New9MNew
Sold Out Positions67Sold Out5MSold Out
Total Postitions332+7.1%129M+8.08%

APLS Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Avoro Capital Advisors Llc$301,400.009.7%12.22M+1M+10%2024-12-31
Ecor1 Capital, Llc$293,228.009.44%11.89M00%2024-12-31
Wellington Management Group Llp$291,009.009.37%11.8M-4M-24.19%2024-12-31
Vanguard Group Inc$247,735.007.97%10.05M+230,450+2.35%2024-12-31
Morgan Stanley$237,407.007.64%9.63M+6M+184.01%2024-12-31
Blackrock, Inc.$159,747.005.14%6.48M+285,621+4.61%2024-12-31
State Street Corp$111,590.003.59%4.53M+484,294+11.98%2024-12-31
Deep Track Capital, Lp$105,420.003.39%4.27M-125,733-2.86%2024-12-31
Octagon Capital Advisors Lp$74,152.002.39%3.01M00%2024-12-31
Siren, L.L.C.$69,449.002.24%2.82M+649,034+29.95%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.